Negative / Null Result ReportOpen accessMedicine· cited by 25

Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study

James D. Doecke; Giovanni Bellomo; Lisa Vermunt; Daniel Alcolea; Steffen Halbgebauer; Sjors G. J. G. In ‘t Veld; Niklas Mattsson; Kateřina Veverová · 2025 · Alzheimer s & Dementia

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

INTRODUCTION: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. METHODS: Plasma samples (n = 1298) were collected from six international centers. Aβ40, Aβ42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrosp

Abstract by James D. Doecke; Giovanni Bellomo; Lisa Vermunt; Daniel Alcolea; Steffen Halbgebauer; Sjors G. J. G. In ‘t Veld; Niklas Mattsson; Kateřina Veverová, Alzheimer s & Dementia (2025) — licensed CC BY 4.0.

Read the full paper (open access)